PMID- 26984361
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160610
LR  - 20240330
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 7
IP  - 2
DP  - 2016 Jun
TI  - Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus 
      Glimepiride in Patients with Type 2 Diabetes on Metformin.
PG  - 269-78
LID - 10.1007/s13300-016-0163-1 [doi]
AB  - INTRODUCTION: Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, 
      has demonstrated sustained improvements in glycemic control and body weight 
      reductions with treatment for up to 104 weeks in a broad range of patients with 
      type 2 diabetes mellitus (T2DM). METHODS: This was a post hoc analysis of 
      individual patient data (N = 1450) from a randomized, double-blind, 
      placebo-controlled, Phase 3 study comparing canagliflozin with glimepiride as 
      add-on to metformin in patients with T2DM during a 52-week core period followed 
      by a 52-week extension period. The number of patients who achieved a reduction 
      from baseline in both HbA1c and body weight with canagliflozin 100 and 300 mg and 
      glimepiride was assessed at Weeks 52 and 104. Safety was recorded as adverse 
      events (AEs) during the study. RESULTS: Canagliflozin 100 and 300 mg provided 
      durable glycemic improvements and body weight reductions compared with 
      glimepiride over 104 weeks. At Week 52, the proportion of patients who achieved 
      reductions in both HbA1c and body weight was 72.4% with canagliflozin 100 mg, 
      78.5% with canagliflozin 300 mg, and 26.8% with glimepiride; similar results were 
      observed at Week 104 (65.5%, 71.1%, and 26.8% with canagliflozin 100 and 300 mg 
      and glimepiride, respectively). The AE profile of canagliflozin was comparable to 
      that observed in previous studies, with increased incidence of AEs related to the 
      mechanism of SGLT2 inhibition (e.g., genital mycotic infections, urinary tract 
      infections, and osmotic diuresis-related AEs) and a low risk of hypoglycemia. 
      CONCLUSION: More patients treated with canagliflozin experienced reductions in 
      both HbA1c and body weight compared with glimepiride for up to 104 weeks. 
      Canagliflozin was generally well tolerated in patients with T2DM when used in 
      combination with metformin. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov 
      identifier, NCT00968812. FUNDING: Janssen Research & Development, LLC.
FAU - Leiter, Lawrence A
AU  - Leiter LA
AD  - Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's 
      Hospital, University of Toronto, Toronto, ON, Canada. leiterl@smh.ca.
FAU - Langslet, Gisle
AU  - Langslet G
AD  - Lipid Clinic, Oslo University Hospital, Oslo, Norway.
FAU - Vijapurkar, Ujjwala
AU  - Vijapurkar U
AD  - Janssen Research & Development, LLC, Raritan, NJ, USA.
FAU - Davies, Michael J
AU  - Davies MJ
AD  - Janssen Scientific Affairs, LLC, Raritan, NJ, USA.
FAU - Canovatchel, William
AU  - Canovatchel W
AD  - Janssen Research & Development, LLC, Raritan, NJ, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00968812
PT  - Journal Article
DEP - 20160316
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC4900973
OTO - NOTNLM
OT  - Body weight
OT  - Canagliflozin
OT  - Glimepiride
OT  - Glycated hemoglobin
OT  - Sodium glucose co-transporter 2 (SGLT2) inhibitor
OT  - Type 2 diabetes mellitus
EDAT- 2016/03/18 06:00
MHDA- 2016/03/18 06:01
PMCR- 2016/03/16
CRDT- 2016/03/18 06:00
PHST- 2016/01/19 00:00 [received]
PHST- 2016/03/18 06:00 [entrez]
PHST- 2016/03/18 06:00 [pubmed]
PHST- 2016/03/18 06:01 [medline]
PHST- 2016/03/16 00:00 [pmc-release]
AID - 10.1007/s13300-016-0163-1 [pii]
AID - 163 [pii]
AID - 10.1007/s13300-016-0163-1 [doi]
PST - ppublish
SO  - Diabetes Ther. 2016 Jun;7(2):269-78. doi: 10.1007/s13300-016-0163-1. Epub 2016 
      Mar 16.